Skip to main content

Table 1 Demographic and clinical characteristics

From: A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients

  Patients (n = 19) Controls (n = 19) p-value
Age at baseline (years) 50.2 (8.6) 49.3 (9.0) 0.76
Education    0.66
High School 2 3  
College 8 8  
Undergraduate Degree 5 2  
Graduate Degree 4 6  
Menopausal status at baseline   0.82
Menstruating 8 9  
Perimenopausal 4 2  
Postmenopausal 7 8  
Cancer stage    
I 3  
II 13  
III 3  
Chemotherapy regimen    
FEC-D (six cycles)1 12  
FEC-D (five cycles) 1   
CD (four cycles) 4  
CDOX (four cycles)2 2  
Type of surgery    
Modified Radical MX 7  
Simple MX 1  
Segmental MX 3  
Lumpectomy 8  
Time between (days)    
Surgery to T1 MRI 49.9 (15.2)  
T1 MRI to chemo 6.2 (4.9)  
End chemo to T2 MRI 32.0 (15.3)  
T1 MRI to T2 MRI 128.8 (23.0) 127.0 (25.0) 0.81
T2 MRI to T3 MRI 406.16 (70.3) 449.7 (106.9) 0.15
  1. Mean (SD) or count values are shown. Units are arbitrary unless otherwise specified. FEC-D: fluorouracil + epirubicin + cyclophosphamide + docetaxel; CD: cyclophosphamide + docetaxel; CDOX: cyclophosphamide + doxorubicin; MX: mastectomy. 1Two cases with epirubicin and one case with bevacizumab; 2one case with paclitaxel.